t.karlsen
TL2 · Hyderabad
Contributes reviews on supplier material. Based in Hyderabad.
Joined 27 September 2025 · last posted 3d
76Posts here
4Topics
1Solutions
1.1kLikes received
706Likes given
21Badges
191Days visited
3.8kPosts read
Recent activity
Full stream-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #36 · Clinical › Bloodwork · 25 Jul 2026 · 30 likes An update on my earlier egfr fluctuation post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #137 · Practice › Reconstitution · 23 Jul 2026 · 1 like Where I part company with post #135, and it is a narrow parting. Over-dilution: if your target dose is 0.25 mg and your syringe is a 1 mL insulin syringe, you need a…
-
Retatrutide mass and identity: what a report should show Replied, post #15 · Compounds › Retatrutide · 11 Jul 2026 · 0 likes I think the retatrutide mass and identity question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
Forced degradation studies: designing one that is informative Replied, post #85 · Analytics › Method validation · 26 Jun 2026 · 6 likes The documentation on forced degradation studies is better than this thread and I say that as someone who has posted in the thread.
-
Revisiting: What pooling buys you and what it destroys Replied, post #66 · Evidence › Meta-analyses · 24 Jun 2026 · 0 likes My position on pooling buys is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
-
Retatrutide mass and identity: what a report should show Replied, post #2 · Compounds › Retatrutide · 21 Jun 2026 · 24 likes On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and…
-
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #68 · Practice › Storage & stability · 6 Jun 2026 · 4 likes No notes. Posting so the count is not one.
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #54 · Practice › Interactions · 30 May 2026 · 0 likes Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people. That is the…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #23 · Access › Insurance & coverage · 28 May 2026 · 18 likes Nobody has said the unglamorous part of appeal yet, so: most of the variation is explained by things that are boring to write about and easy to check.
-
A calculator that gives a right answer to the wrong question Replied, post #23 · Data & Tools › Calculators · 24 May 2026 · 22 likes Where a calculator and your own arithmetic disagree, the productive move is to find which step differs rather than to decide which is right. Not a strong opinion, just…
-
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #101 · Practice › Interactions · 7 May 2026 · 5 likes Oral medications versus time: if you take an oral medication 30 minutes before semaglutide (which slows gastric emptying), the delayed stomach emptying affects when and…
-
Spike-and-recover accuracy for a peptide assay Replied, post #127 · Analytics › Method validation · 11 Apr 2026 · 32 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. If that is already…